What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?

被引：6

作者：

Vanoli, Fiammetta ^{[1
,2
]}

Mantegazza, Renato ^{[1
]}

机构：

[1] Fdn IRCCS Ist Neurol Carlo Besta, Neuroimmunol & Neuromuscular Dis Dept, Milan, Italy

[2] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy

来源：

关键词：

Myasthenia gravis; monoclonal antibodies; immunosuppression; biological drugs; C5; FcRn; RITUXIMAB;

D O I：

10.1080/14656566.2022.2122710

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1471 / 1474

页数：4

共 50 条

[21] ON TREATMENT OF MYASTHENIA GRAVIS
SZOBOR, A
ACTA MEDICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1969, 26 (02) : 103 - &
[22] TREATMENT OF MYASTHENIA GRAVIS
STONE, CT
RIDER, JA
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1949, 141 (02): : 107 - 111
[23] TREATMENT OF MYASTHENIA GRAVIS
不详
LANCET, 1947, 252 (APR5): : 453 - 453
[24] TREATMENT OF MYASTHENIA GRAVIS
不详
BMJ-BRITISH MEDICAL JOURNAL, 1962, (5313): : 1204 - +
[25] THE TREATMENT OF MYASTHENIA GRAVIS
不详
BMJ-BRITISH MEDICAL JOURNAL, 1947, 2 (4536): : 966 - 966
[26] TREATMENT OF MYASTHENIA GRAVIS
不详
LANCET, 1950, 259 (AUG19): : 293 - 295
[27] TREATMENT OF MYASTHENIA GRAVIS
不详
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1947, 133 (16): : 1252 - 1252
[28] Treatment of Myasthenia Gravis
Farmakidis, Constantine
Pasnoor, Mamatha
Dimachkie, Mazen M.
Barohn, Richard J.
NEUROLOGIC CLINICS, 2018, 36 (02) : 311 - +
[29] Treatment of myasthenia gravis
McCullough, M.
AUSTRALIAN PRESCRIBER, 2007, 30 (06) : 160 - 160
[30] Treatment of myasthenia gravis
Laurent, LPE
Walker, M
LANCET, 1943, 2 : 367 - 367